Curis 10-Q: $40.9M Nine-Month Loss, Going Concern, Runway Into Q1 2027
CRIS sits 37% above its 52-week low of $0.325 on light trading volume (0.2× avg).
Summary
Curis's Q3 10-Q confirms a $40.9 million nine-month net loss, $5.0 million of cash, and substantial doubt about going concern, with runway only into Q1 2027 after the October private placement.
Key Events · Earnings and Guidance · CRIS
-
Going Concern Reiterated
Curis concluded it does not have sufficient cash on hand to fund operations for 12 months from the filing date; $5.0 million of cash at September 30 plus about $7.5 million of October private-placement proceeds funds operations only into the first quarter of 2027.
-
Nine-Month Loss Widens
Net loss was $40.9 million for the nine months ended September 30, 2026 versus $26.9 million a year earlier, with revenue at zero after the Erivedge royalty sale and $24.4 million of cash used in operations.
-
Warrant Remeasurement Is Non-Cash
A $10.86 million change in fair value of warrant liabilities hit the nine-month results; this is a non-cash mark-to-market entry, not new dilution or a cash payment. The January 2026 Series B warrants expired unexercised on September 28, 2026 after their strike reset to $7.50.
-
Nasdaq Delisting Risk
Curis received a delist determination on November 2, 2026 after 30 days below the $1.00 bid threshold and requested a hearing on November 9, 2026; a November 18, 2026 special meeting will vote on a reverse split of 1-for-5 to 1-for-12.
Analysis · CRIS · Life Sciences
The Q3 numbers were already out on November 12, but the full 10-Q is where the survival math becomes explicit: $5.0 million of cash at September 30 plus roughly $7.5 million from the October private placement funds operations only into the first quarter of 2027, and management states plainly it does not have enough cash for the next 12 months. That going-concern conclusion sits alongside a Nasdaq delist determination received November 2 and a November 18 shareholder vote on a reverse split — a company that must raise capital again within months while its stock trades below $1.00. The $10.86 million warrant fair-value charge for the nine months is a non-cash mark-to-market entry, not new dilution or a cash outflow; the real dilution is the October placement and the post-quarter exercises of August warrants.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.33 to $28.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.